Published in Medical Letter on the CDC and FDA, March 5th, 2006
IT-101 is a combination of the company's patented polymer technology, Cyclosert, and the anticancer compound camptothecin, used to treat patients with unresectable or metastatic solid tumors. The objectives of the phase 1 clinical protocol submitted with the IND are to evaluate the safety, pharmacokinetics and tolerability of IT-101 in humans.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.